Compare Robinhood Markets, Inc. (HOOD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Novartis AG — how do they compare? Robinhood Markets, Inc. trades at $108.9 (market cap $96.21B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 2.8× Robinhood Markets, Inc.'s market cap, and Novartis AG pays a 3.31% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Novartis AG for 82 Days on average.
| HOOD | NVS | |
|---|---|---|
Market Cap | $96.21B | $268.57B |
Volume | 22,572,153 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $152.46 | $168.62 |
52-Week Low | $65.16 | $121.80 |
Typical Hold Time | 75 Days | 82 Days |
Enterprise Value | $102.75B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $109.51, down 2.22% on the day, with a bullish technical signal and strong support at $108. The company reported robust 2025 results with $4.47B revenue and $1.88B net income, though valuation ratios like a P/E of 47.35 remain elevated. Recent news highlights expansion into 24/7 stock trading and AI-powered features, signaling growth initiatives.
Outlook is positive with a $137 consensus price target and 77% buy ratings, but high valuation and competitive pressures pose risks. Earnings beat in Q2 2026 and upcoming Q3 results on October 27, 2026, are key catalysts, though regulatory scrutiny and market volatility could impact momentum.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
